By Mill Chart
Last update: Apr 25, 2024
Unearth the potential of JOHNSON & JOHNSON (NYSE:JNJ) as a dividend stock recommended by our stock screening tool. NYSE:JNJ maintains a robust financial footing and delivers a sustainable dividend. We'll delve into the details below.
ChartMill assigns a Dividend Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing various dividend elements, such as yield, historical performance, dividend growth, and sustainability. NYSE:JNJ has been awarded a 7 for its dividend quality:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NYSE:JNJ scores a 8 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:JNJ was assigned a score of 9 for profitability:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Our latest full fundamental report of JNJ contains the most current fundamental analsysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
JOHNSON & JOHNSON
NYSE:JNJ (5/3/2024, 7:04:00 PM)
After market: 149.7 +0.43 (+0.29%)149.27
-0.65 (-0.43%)
As new robotic surgery systems loom, Intuitive Surgical investors await a "game-changer."
One of these stocks boosted its payouts by as much as 13%.
One of these stocks boosted its payouts by as much as 13%.
The Pharmaceutical giant say they are taking steps to resolve a multi-billion dollar cancer-related lawsuit with thousands of individuals over claims that chemicals in their baby powder had caused certain cancers.
Investors should look for opportunities to buy these leading healthcare companies, each of which posted strong Q1 results.
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
The offer is the company’s third attempt to resolve tens of thousands of claims that its baby powder caused ovarian cancer and mesothelioma.
Cannabis stocks are falling on Wednesday as shares of marijuana companies are giving up some of the massive gains they saw yesterday.
CytomX stock is rising higher on Wednesday as CTMX investors get an update on its upcoming earnings and clinical trial news.